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Gene Therapy 2017: Progress and Future Directions
AM Keeler, MK ElMallah and TR Flotte∗
INTRODUCTION: GENE THERAPY IN 2017
Gene therapy has changed dramatically in the 28 years
since the first human gene transfer experiment in 1989.
Alipogene tiparvovec, GlyberaR R©, a recombinant adeno-
associated virus (rAAV) product for lipoprotein lipase defi-
ciency, and Strimvelis R©, a lentivirus vector for severe com-
bined immune deficiency are approved in Europe. An rAAV2
product for a congenital form of blindness is currently under
review in the United States, likely to be followed by numerous
other gene therapies.
Nonviral gene transfer
The success of gene therapy has largely been driven by
improvements in nonviral and viral gene transfer vectors. An
array of physical and chemical nonviral methods have been
used to transfer DNA and mRNA to mammalian cells and a
substantial number of these have been developed as clinical
stage technologies for gene therapy, both ex vivo and in vivo.
Cationic liposome technology is based on the ability of
amphipathic lipids, possessing a positively charged head
group and a hydrophobic lipid tail, to bind to negatively
charged DNA or RNA and form particles that generally enter
cells by endocytosis. Some cationic liposomes also con-
tain a neutral co-lipid, thought to enhance liposome uptake
by mammalian cells.4–7 Similarly, other polycations, such as
poly-l-lysine and polyethylene-imine, complex with nucleic
acids via charge interaction and aid in the condensation of
DNA or RNA into nanoparticles, which are then substrates
for endosome-mediated uptake.8 Several of these cationic-
nucleic acid complex technologies have been developed as
potential clinical products, including complexes with plasmid
DNA (pDNA), oligodeoxynucleotides, and various forms of
synthetic RNA.9–11
Modified (and unmodified or “naked”) DNA, RNA, and
oligonucleotides have also been shown to mediate suc-
cessful gene transfer in a number of circumstances. These
include the use of pDNA by direct intramuscular injection for
DNA vaccines, the use of intratumoral injection of pDNA to
deliver cytokine and/or suicide genes, systemic (s.c. or i.v.)
injection of antisense nucleotides to induce RNAse H1 or
exon-skipping.12–14 The most recent of these developed for
induction of RNAi are discussed in a later section.
Ex vivo introduction of pDNA and/or other nucleotides
using physical methods has been well developed for certain
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cell types, including T lymphocytes.15 Electroporation tech-
niques have become the standard with T cells for the intro-
duction of a variety of molecular cargoes, including ribonu-
cleoproteins composed of Cas9 and short-guide RNAs for
genome editing (see section below) and transposons for
long-term integration of transgenes.
Gammaretrovirus and lentivirus vectors
Many within the gene therapy field consider viruses as the
ultimate vectors for the delivery of therapeutic tools, and the
number of gene therapy clinical trials reflects this bias.16–20
Retroviruses were the first class of viruses to be harnessed
for mammalian and human gene transfer, and they are at
the leading edge of products that show clinical efficacy1
(Figure 1).
For example, direct clinical benefit with chimeric antigen
receptor T (CAR-T) cells is a promising novel therapy for
many malignancies. CAR-T cells are produced by ex vivo
transduction of T cells with lentiviral vectors.21–23 Exciting
results with B-cell lymphomas and leukemia eradication was
seen when CAR-T cells are directed against the B-cell sur-
face antigen, CD19.24,25 However, because CD19 is a pan-
B cell marker, one side effect is normal B-cell depletion.
Thus, to try and restrict normal B-cell depletion after CAR-
T cell administration, a recent study refined CD19 CAR-T
cells to recognize κ-restricted cells, thereby excluding nor-
mal B-cells from targeted destruction.26 In addition, other
tumor-associated antigens have been targeted with some
clinical success.21,27,28 Although most of these trials have
utilized autologous T cells, one recent report showed effi-
cacy in “off-the-shelf” (TCR−/CD52−) allogeneic anti-CD19
CAR-T cells. These T-cells not only are transduced with the
lentivirus expressing a chimeric antigen receptor, but they
also have their endogenous T-cell receptor knockout via tran-
scription activator-like effector nuclease TALEN-mediated
genome editing.29,30
Another prominent example of clinically effective gene
therapy with gammaretrovirus and lentivirus vectors is ex
vivo transduction of hematopoietic stem cells to treat con-
ditions such as severe combined immunodeficiency (SCID).
These include both X-linked SCID gammaretrovirus31 and
lentivirus32 therapies, as well as SCID due to adenosine
deaminase-SCID deficiency. In fact, the lentiviral StimvelisR
recently received European Market Authorization to treat
patients with adenosine deaminase-SCID deficiency.33 In
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Figure 1 Timeline of major events in clinical gene therapy. A few selected key dates in the history of human gene therapy are depicted,
with the dates indicated on the x-axis. AAV2, adeno-associated virus type 2; Ad5, adenovirus type 5; CF, cystic fibrosis; CRISPR, clus-
tered regularly interspaced short palindromic repeats; FIX, clotting factor IX; LPL, lipoprotein lipase; OTC, ornithine transcambamylase;
RNAi, RNA inhibition; RPE65, 65 kilo-Dalton retinal pigment epithelial protein; RV, gammaretrovirus; SCID-ADA, severe combined immune
deficiency due to adenosine deaminase deficiency; TIL, tumor-infiltrating lymphocytes.
Table 1 Gene therapy clinical trials for monogenic diseases in phases III/IV
Disease Vector Outcomes Location of the Trial References
LPLD AAV-Glybera Improved lipid profile and
decreased pancreatitis
The United States 113–115
X-linked adrenoleukodystrophy Lentivirus Improved neurologic
development
France 19
Thalassemia major Lentivirus Decreased transfusion
need
The United States 16
X-linked/ choroideremia rentinal
disease (REP1)
AAV2 Improved vision The United States- multiple countries 17,116
LCA AAV2 Improved low-light vision The United States 20,117,118
Leber hereditary optic
neuropathy
AAV2 Improved vision France - multiple countries including US 18,119
AAV, adeno-associated virus; LCA, Leber congenital amaurosis type 2; LPLD, lipoprotein lipase deficiency.
addition, similar clinical effectiveness was seen in X-linked
adrenoleukodystrophy between patients treated with ex
vivo lentiviral correction and those treated with allogeneic
hematopoietic cell transplantation (Table 1).19 Other promis-
ing retroviral hemopoietic stem-cell gene therapies include
lentiviral therapies for metachromatic leukodystrophy34 and
both gammaretroviral and lentiviral therapies for Wiskott-
Aldrich syndrome. In Wiskott-Aldrich syndrome, lentiviral
therapies showed a safer profile than gammaretrovirus vec-
tors, relative to the risk of insertional mutagenesis.35,36
Adenoviruses and oncolytic viruses
Adenoviruses (Ads) were also used early on in gene therapy
clinical trials, and are one of the most studied and published
viral vectors (Figure 1). Ads have robust transduction pro-
files, particularly in the liver, but they were also accompa-
nied by robust immune responses. Different levels of atten-
uation of the virus can be achieved by removing different
components, including complete removal of all genetic infor-
mation – the so-called “gutless” vectors.37 Unfortunately,
early clinical trials for gene correction using Ads did not
have many clinical successes, and one trial resulted in a
tragic fatality.38 Additional hurdles seen with systemic deliv-
ery include nonspecific binding to blood components lead-
ing to viral inactivation. In addition, a majority of adults
have antibodies against common Ad5 serotypes.39,40 Fur-
ther modifications of Ad vectors, such as making chimeric
vectors, and chemical modifications have helped overcome
some of the early challenges with liver targeting and host
immunity.37 However, Ads have recently been used in can-
cer treatment as oncolytic viruses. A number of clinical trials
using Ad to target a number of different cancers, such as
Clinical and Translational Science
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prostate, ovarian, bladder, and refractory solid tumors, have
been promising.41–45 In this type of therapy, robust immune
responses are beneficial for therapeutic outcomes. Many
other viruses have been used as oncolytic viruses, such
as: vaccine virus; herpes virus; Coxsackievirus, reovirus,
parvovirus, vesicular stomatitis virus, Newcastle disease,
measles virus, polio virus, and Seneca Valley virus.46 The
first clinically approved oncolytic virus is Talimogene Laher-
parepvec (Imlygic R©; Amgen, South San Francisco, CA),
which is a genetically modified herpes virus expressing
human granulocyte-macrophage colony-stimulating factor.
Talimogene Laherparepvec has been approved for the treat-
ment of advanced melanoma.47–50 Thus, Ad, one of the ear-
liest vectors in the gene therapy field, may find a new role in
cancer gene therapy along with other oncolytic viruses.
Recombinant adeno-associated virus vectors
Recombinant adeno-associated virus (rAAV) vector-
mediated gene therapy has also proven to be efficacious
in certain conditions.2 Hundreds of clinical trials have been
performed using rAAV viral vectors for recessive monogenic
disorders, with the first human rAAV injection performed
almost 25 years ago.51 Examples of clinical efficacy with
rAAV include data from trials with hemophilia B,52,53 spinal
muscular atrophy (unpublished), alpha 1 antitrypsin,54,55
and Leber congenital amaurosis.56 In hemophilia B, a single
systemic administration of rAAV carrying the human factor
IX gene resulted in a multiyear sustained expression of
factor IX levels at 1–6% of normal.52,53 Similarly, in alpha
1 antitrypsin, intramuscular injections of AAV1 carrying the
AAT gene resulted in sustained AAT expression for 5 years
(Gruntman et al., unpublished). Ongoing clinical trial in spinal
muscular atrophy resulted in improved survival in patients
with spinal muscular atrophy type 1. Patients with Leber
congenital amaurosis had partial restoration of their vision
after receiving therapy with rAAV2 vector carrying the human
retinal pigment epithelium 65kDa gene.55
Other rAAV vectors are on their way through preclinical
and clinical proof-of-concept studies Table 1. Recently, a
number of proof-of-concept studies have been completed
using rAAV technology for correction of single gene disor-
ders targeting a wide variety of tissues. The clinical success
of the Leber congenital amaurosis trial, have led to a num-
ber of studies targeting genetic diseases of the retina.3 Dis-
eases of the central nervous system have also had some
important proof-of-concept studies, along with metabolic
and skeletal diseases.57–62 Additionally, rAAVs have been
used to treat diseases other than monogenic disorders,
such as interferon-beta delivery to treat the aggressive brain
cancer glioblastoma multiforme,63 and to provide treatment
for infectious diseases, such as human immunodeficiency
virus64 and influenza.65
Despite these many successes with rAAV and other viral
gene therapies, the future of the field of gene therapy may
lie in new technologies. Examples of these technologies
stem from the discovery of RNA interference in C. ele-
gans by Fire et al.,66 discovery of the host defense system
CRISPR/Cas9 in S. pyogenes,67 and finally from the dis-
covery of new vectors through co-evolution and directed
evolution.
Figure 2 Structure of adeno-associated virus 2 (AAV2).113 The
icosahedral structure of the virus capsid is shown. Note that this
structure is symmetrical across a twofold, threefold, and fivefold
axis of symmetry. The ability of the AAV vectors to transduce vari-
ous cell types largely depends on variation in amino acid moieties
highlighted in color.
Novel adeno-associated virus capsids
The rAAV is a simple and ubiquitous wildtype virus that
occurs naturally in humans (Figure 2). Even wildtype adeno-
associated virus (AAV) is naturally a vector given its repli-
cation dependence on helper viruses. However, antibodies
against AAV can decrease the efficacy of rAAV-mediated
gene therapy. A lot of work has recently gone into updat-
ing the existing repertoire of natural variants of AAV viruses
by both rational design and directed evolution. For exam-
ple, pioneering work by Gao et al.,68,69 greatly added hun-
dreds of natural variants to the gene therapists tool kits
and new AAV variants are still being discovered. In addi-
tion, many novel vectors have been rationally engineered.
These new vectors allow avoidance of the immune system
and enable tissue-specific tropism to target exact organs
involved in the disease of interest. Rationally engineered
viruses, such as AAV2g9, have been developed to exploit
the benefits from parental variants, such as the galac-
tose receptor footprint from AAV9, while creating unique
transduction profiles, such as central nervous system-
restricted transduction.70,71 Furthermore, directed evolution
was used to create unique transduction profiles. Using a cre-
recombination-based adeno-associated virus-targeted evo-
lution (CREATE) strategy, novel AAV variants can now achieve
widespread expression through the central nervous system
in mice.72 However, improved transduction efficiency is not
only limited to the CNS but has also been more efficient in
muscles,73 as well as in human and murine livers.74
RNAi
The discovery of RNAi allowed for a shift from gene therapy
focused on gene augmentation to a focus on downregula-
www.cts-journal.com
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tion of gene expression for diseases in which pathology is
caused by toxic gain of function. Some of the first clinical
therapies used small-interfering RNA in diseases of the liver;
small-interfering RNA sequences were developed to target
hepatocytes75 in which knockdown of gene expression have
a therapeutic effect on disease pathogenesis. Examples of
this include therapy for transthyretin-mediated amyloidosis76
and complement-mediated diseases.77
However, in order to achieve long-term knockdown, amore
stable approach is to use another RNAi pathway, specifically
delivery of synthetic microRNA (miRNA), which can be con-
tinuously expressed by viral vectors. Interestingly, the dis-
covery of exogenous RNA-mediated downregulation by Fire
et al.,66 was preceded by the discovery of miRNA in C. ele-
gans by Lee et al.78 and Wightman et al.79 Both discoveries
utilize the same enzymatic pathway that allows for exploita-
tion of natural miRNA in mammalian systems for therapeu-
tic purposes. The rAAV delivery platform can be used to
continually express synthetic miRNA “genes” to downregu-
late a gene by sequence-specific targeting. This technology
has been used to treat dominant disorders, such as Hunt-
ington’s disease, in which a toxic gain of function causes
neurological disease by increased number of CAG repeats
in the huntingtin’s gene.80–82 It has also been used to treat
SOD1-mediated amyotrophic lateral sclerosis in a murine
model of amyotrophic lateral sclerosis, in which motor neu-
ron disease is caused by toxic gain of function of the SOD1
protein.58,83 Furthermore, this system can be used to treat
diseases in which both a loss-of-function and a toxic gain of
function is associated with a certain mutation. For example,
in alpha-1 antitrypsin (AAT) deficiency, a mutant AAT protein
(the PiZ protein) causes both liver disease by toxic accumu-
lation of the protein and emphysematous lung disease by an
absence of AAT. For AAT, rAAV was used to deliver a miRNA
designed to knock-down expression of PiZ causing liver
disease while simultaneously augmenting expression of the
normal AAT transgene to prevent lung disease.84
CRISPR/Cas9 genome editing
Novel exciting gene editing tools offer a more elegant and
precise method of treating genetic diseases. There have
been efforts on this front through ex vivo homologous recom-
bination, TALENS and Zinc Finger Nucleases. However, none
have the promise of the recently discovered clustered regu-
larly interspersed short palindromic repeats (CRISPR)/crispr-
associated protein 9 (Cas9).67 CRISPR/Cas9 has trans-
formed biomedical research. This technology was initially
discovered in bacteria and archaea as a means for these
organisms to defend themselves against invading viruses.85
Using CRISPR/Cas9, many are targeting specific regions of
the human genome in an attempt to achieve a therapeutic
effect.86–88 Targeting sequence specificity, similar to that of
the RNAi approach, allows for the success and efficiency of
CRISPR/Cas9.89–91 In order for the system to work, synthetic
short-guide RNAs are delivered in combination with a Cas-
like enzyme, which allows for double-stranded breaks in the
host DNA in a specific manner. Expression of genes can be
disrupted by host DNA repair mechanisms in which a small
insertion and/or deletion (indel) of two to six nucleotides gen-
erally results in a frameshift mutation and termination.86,87
However, genes can also be repaired by providing a ds-DNA
template with the short-guide RNA and Cas-like enzyme,
allowing homology-dependent recombination to occur.
Although CRISPR/Cas9 therapies are still in early devel-
opment, some therapeutic approaches have already been
demonstrated for genetic diseases and for Duchenne mus-
cular dystrophy92 and liver disease fumarylacetoacetate
hydrolase deficiency.93 One of the major challenges is in
the delivery of the components necessary to complete the
editing process. Viral vectors like rAAV have been sug-
gested, but long-term expression, one advantage of rAAV,
in augmentation or downregulation therapy becomes a dis-
advantage in the CRISPR/Cas9 genome editing in which
short-term expression is all that is necessary to make the
genetic changes. Conversely, vectors like adenovirus, which
have robust expression albeit only in the short term, would
be ideal if immune responses were not robust and led to
clearance of virally targeted cells. However, the remaining
challenges should not dissuade scientists from perusing
these types of therapies as the potential for several clinical
applications are impressive.
CONCLUSION/FUTURE DIRECTIONS
The knowledge gained within the field over the past sev-
eral decades provides much hope for the future of gene
therapy. The exciting possibility of treating many genetic
and infectious disorders is now close to a reality with the
success of rAAV in bench-work and clinical trials, novel
vector engineering, and the recent discoveries of miRNAs,
and CRISPR/Cas9. We are on the brink of having therapies
approved for clinical usage in the United States, and the
European Medicines Agency already has two approved ther-
apies. AAV encoded miRNAs will soon be tested in clinical
trials, whereas technologies, such as CRISPR/Cas9, are still
in proof-of-concept stages but holdmassive clinical promise.
Moving forward, the ability to exploit new molecular tools,
such as RNAi and CRISPR/Cas9, should be able to make
use of some of the clinical development paradigms from ear-
lier gene therapy trials. Examples of this might include basic
preclinical and clinical study designs to examine biodis-
tribution of vector components and risk for carcinogen-
esis. One important distinction exists, however, between
conventional viral gene therapy vectors and newer RNA-
guided mechanisms. The toxicity observed with viral vec-
tors has generally been consistent with toxicity of the viruses
on which each vector is based.94 This is true of both Ad
vector-mediated inflammation and gammaretrovirus vector-
mediated leukemia.95–97 In the case of CRISPR/Cas9, a sys-
tem is being used that does not occur in mammalian cells
at all, as far as is currently known.67,98 Likewise, although
miRNA-mediated gene regulation is seen inmammalian cells,
the understanding of miR-based diseases is at a fairly early
stage. Thus, the modelling possible toxicities from such ther-
apies are based more on theoretical concerns than on past
experiences.
Nonetheless, it seems likely that certain genetic dis-
eases will be approachable with CRISPR/Cas9 and RNAi-
based therapy that were not approachable with prior
methods.86–88,92 Specifically, the ability to treat autosomal
Clinical and Translational Science
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dominant disorders is a feature of both of these methods. In
addition, CRISPR/Cas9 presents the ability to repair a gene in
situ, allowing for preservation of all of the elements required
for normal physiologic regulation of the gene of interest by
its own promoter and enhancers.99,100
This has led some to speculate that CRISPR/Cas9 could
actually enable a permanent and definitive germ-line correc-
tion of a genetic disorder.101,102 One such study, performed
in nonviable human embryos, demonstrated the feasibility of
doing so in addressing hemoglobinopathies.103 Clearly, such
an approach is not currently deemed to fall within ethical
guidelines,102 although some have pointed out that thera-
peutic transfer of whole mitochondria has been allowed even
though mitochondrial DNA will likely be passed down in the
germ line. It is conceivable, however, that a purely thera-
peutic approach, intended to cure a disease rather than to
enhance, could be allowable in the future if appropriate ques-
tions about safety and efficacy can be addressed. This was
anticipated by the joint statement from the National Academy
of Sciences and the National Academy of Medicine.104 If that
were to transpire in the future, it could represent the most
definitive treatment for families with a genetic defect that has
ever been attempted.
More near-term, the ability to control gene expression
in the context of gene transfer may be a more realistic
goal. A number of promoter systems inducible by small
molecule drugs have shown excellent dynamic range for
gene regulation in cell culture and in animal models. Among
these are the tetracycline inducible and repressible sys-
tems, and those based on modified estrogen and proges-
terone receptors.105–108 None of these has achieved clinical
translation to date, primarily due to the immune responses
to transcriptional activator domains that are not human in
origin.109–111 The field of synthetic biology has produced
two-component RNA-based systems, so-called “toehold
switches” that may have superior characteristics in cer-
tain circumstances.112 The added complexity of these mul-
ticomponent systems could be particularly useful for trans-
gene products with a relatively narrow therapeutic window
of expression. This sort of adaptation of different gene ther-
apy platforms to different disease targets will likely represent
the primary challenge and opportunity facing gene therapy
researchers in the coming years.
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